immunophenoscores ips Search Results


immunophenoscore ips values  (Immunome Inc)
86
Immunome Inc immunophenoscore ips values
Association of the PCD-based risk signature with immune characteristics, immunotherapy response, and mutation status in melanoma. (A–D) Violin plots CAF, Merck18 immune-related score, T cell exclusion, and MSI between high- and low-risk groups in the TCGA-SKCM cohort. (E) Kaplan–Meier survival curve showing significantly worse survival in the high-risk group of the IMvigor210 cohort. (F) Boxplot comparing risk scores between high- and low-risk groups in IMvigor210, confirming elevated scores in high-risk patients. (G, H) Risk scores are significantly higher in non-responders vs. responders to immunotherapy in the GSE35640 and GSE78220 cohorts. (I–P) Kaplan–Meier survival analyses in the IMvigor210 cohort, stratified by immune checkpoint gene expression levels and risk group. (Q) Violin plot showing TMB is significantly higher in high-risk patients. (R) Kaplan–Meier curve indicating that combined high TMB and low risk score predicts the best survival outcomes, whereas low TMB and high risk confers the poorest prognosis. (S) Violin plots of <t>IPS</t> across CTLA4/PD1 combinations. (T) Heatmap of top mutated genes sorted by fold change between high- and low-risk groups in TCGA-SKCM. (U–Z) Kaplan–Meier survival curves comparing mutation vs. wild-type status of representative genes. *P<0.05; **P<0.01; ***P<0.001. PCD, Programmed Cell Death; CAF, Cancer-Associated Fibroblast; MSI, Microsatellite Instability; TMB, Tumor Mutational Burden; IPS, <t>Immunophenoscore;</t> CR, Complete Response; PR, Partial Response; SD, Stable Disease; PD, Progressive Disease; TCGA, The Cancer Genome Atlas; SKCM, Skin Cutaneous Melanoma.
Immunophenoscore Ips Values, supplied by Immunome Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/immunophenoscores+ips/immunophenoscore+ips/pmc12406059-122-0-8
Average 86 stars, based on 1 article reviews
immunophenoscore ips values - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

Image Search Results


Association of the PCD-based risk signature with immune characteristics, immunotherapy response, and mutation status in melanoma. (A–D) Violin plots CAF, Merck18 immune-related score, T cell exclusion, and MSI between high- and low-risk groups in the TCGA-SKCM cohort. (E) Kaplan–Meier survival curve showing significantly worse survival in the high-risk group of the IMvigor210 cohort. (F) Boxplot comparing risk scores between high- and low-risk groups in IMvigor210, confirming elevated scores in high-risk patients. (G, H) Risk scores are significantly higher in non-responders vs. responders to immunotherapy in the GSE35640 and GSE78220 cohorts. (I–P) Kaplan–Meier survival analyses in the IMvigor210 cohort, stratified by immune checkpoint gene expression levels and risk group. (Q) Violin plot showing TMB is significantly higher in high-risk patients. (R) Kaplan–Meier curve indicating that combined high TMB and low risk score predicts the best survival outcomes, whereas low TMB and high risk confers the poorest prognosis. (S) Violin plots of IPS across CTLA4/PD1 combinations. (T) Heatmap of top mutated genes sorted by fold change between high- and low-risk groups in TCGA-SKCM. (U–Z) Kaplan–Meier survival curves comparing mutation vs. wild-type status of representative genes. *P<0.05; **P<0.01; ***P<0.001. PCD, Programmed Cell Death; CAF, Cancer-Associated Fibroblast; MSI, Microsatellite Instability; TMB, Tumor Mutational Burden; IPS, Immunophenoscore; CR, Complete Response; PR, Partial Response; SD, Stable Disease; PD, Progressive Disease; TCGA, The Cancer Genome Atlas; SKCM, Skin Cutaneous Melanoma.

Journal: Frontiers in Immunology

Article Title: Programmed cell death-driven remodeling of the melanoma microenvironment enables prognostic stratification and therapeutic prediction

doi: 10.3389/fimmu.2025.1612217

Figure Lengend Snippet: Association of the PCD-based risk signature with immune characteristics, immunotherapy response, and mutation status in melanoma. (A–D) Violin plots CAF, Merck18 immune-related score, T cell exclusion, and MSI between high- and low-risk groups in the TCGA-SKCM cohort. (E) Kaplan–Meier survival curve showing significantly worse survival in the high-risk group of the IMvigor210 cohort. (F) Boxplot comparing risk scores between high- and low-risk groups in IMvigor210, confirming elevated scores in high-risk patients. (G, H) Risk scores are significantly higher in non-responders vs. responders to immunotherapy in the GSE35640 and GSE78220 cohorts. (I–P) Kaplan–Meier survival analyses in the IMvigor210 cohort, stratified by immune checkpoint gene expression levels and risk group. (Q) Violin plot showing TMB is significantly higher in high-risk patients. (R) Kaplan–Meier curve indicating that combined high TMB and low risk score predicts the best survival outcomes, whereas low TMB and high risk confers the poorest prognosis. (S) Violin plots of IPS across CTLA4/PD1 combinations. (T) Heatmap of top mutated genes sorted by fold change between high- and low-risk groups in TCGA-SKCM. (U–Z) Kaplan–Meier survival curves comparing mutation vs. wild-type status of representative genes. *P<0.05; **P<0.01; ***P<0.001. PCD, Programmed Cell Death; CAF, Cancer-Associated Fibroblast; MSI, Microsatellite Instability; TMB, Tumor Mutational Burden; IPS, Immunophenoscore; CR, Complete Response; PR, Partial Response; SD, Stable Disease; PD, Progressive Disease; TCGA, The Cancer Genome Atlas; SKCM, Skin Cutaneous Melanoma.

Article Snippet: Immunophenoscore (IPS) values were obtained from The Cancer Immunome Atlas (TCIA) and stratified by CTLA4/PD1 combinatorial status.

Techniques: Mutagenesis, Gene Expression